Skip to content

Nevirapine studied as pre-exposure prophylaxis for HIV: safe in 200 mg dose

New erectile dysfunction drug has interaction with HIV protease inhibitors

Lipid increase not needed for HIV protease inhibitors to trigger cardiovascular problems

If one drug fully active, salvage HAART effective after treatment interruption

GSK acquire rights to develop new CCR5 antagonist

Skeletal muscle damage: emerging toxicity of HIV therapy?

Lipodystrophy has uneven impact on quality of life, says study

Triomune equivalent to branded HIV drugs

New Fill injections improve facial appearance, reduce anxiety, within 3 months